Johnson & Johnson (JNJ) said Tuesday it expects its pending acquisition of Intra-Cellular Therapies to dilute adjusted earnings per share by about $0.25 in full-year 2025, an improvement from the $0.30 to $0.35 previously projected during the company's Q4 earnings call.

The company expects the deal to contribute about $700 million in incremental sales, increasing 2025 sales growth by about 0.8%. In 2026, earnings dilution is expected to narrow to roughly $0.21 per share as operational accretion partially offsets annualized financing costs.

Johnson & Johnson expects to complete the acquisition on or around April 2, following shareholder approval on March 27.

The company plans to include these estimates in its full-year 2025 financial outlook when it reports Q1 results on April 15. Upon completion of the deal, Intra-Cellular Therapies' common stock will cease trading on the Nasdaq Global Select Market.